TWi Biotechnology announced that its oral prodrug NORA520, developed for postpartum depression (PDD) and major depressive disorder (MDD), has completed patient enrollment in its Phase II clinical trial, with the readout expected in the fourth quarter of this year. On November 16, the company also disclosed receipt of the U.S. FDA Type C meeting minutes.

According to the FDA Type C meeting, before applying for approval under the 505(b)(2) pathway, NORA520 will require a bridging study and safety studies, with trial design and methods subject to FDA approval. The ongoing Phase II trial, if results meet expectations, may serve as the pivotal trial for future submission.

TWi Biotechnology stated that after the Phase II readout in Q4, it plans to submit proposals for the bridging and safety studies and will further negotiate trial design and methods with the FDA.

Regarding the market, the company noted that postpartum depression affects approximately 10–20% of mothers. According to Fortune Business Insights, the global postpartum depression market is projected to grow from $79.9 million in 2024 to $970 million by 2032, representing a compound annual growth rate (CAGR) of 36.7%.

In addition to NORA520, TWi Biotechnology is advancing two other programs: AC-203 for simplex epidermolysis bullosa (EBS) and AC-1101 for granuloma annulare and atopic dermatitis. General Manager Jeffrey Tsai stated that AC-203 is progressing through global multi-country Phase II/III trials, with interim analysis and licensing discussions planned for next year, while AC-1101 is pursuing orphan drug designation with the FDA.

Chairperson Wu Yi-Jun previously indicated that TWi Biotechnology is advancing all three programs—NORA520, AC-203, and AC-1101—with licensing activity expected to peak next year.

Resource: 安成生技產後憂鬱新藥本季解盲 昨接獲美國FDA Type C會議紀錄